This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.

Phase 3

Novartis Pharmaceuticals

Everolimus
Sirolimus